Philadelphia cell therapy developer Century Therapeutics has added a new drug candidate to its pipeline focused on potentially curing Type 1 diabetes, an autoimmune disease that afflicts 2 million people in the U.S.
“There is a massive unmet need in Type 1 diabetes,” said Brent Pfeiffenberger, the company’s CEO. “Type 2 diabetes gets a lot of press, but you have 9 million patients worldwide with Type 1.”

Century Therapeutics (NASDAQ: IPSC) began exploring the use of its technology platform for Type 1 diabetes in March, but did not say anything publicly until it released its third-quarter financial report earlier this month.

“We wanted to make sure we had the validating data sets behind it,” Pfeiffenberger said. “Over the course of the year, we started to see data emerging that really put us in a position to say this has tremendous potential.”

Read more